159
Participants
Start Date
December 31, 2014
Primary Completion Date
February 27, 2018
Study Completion Date
February 27, 2018
AZD0530 100mg daily
All patients in experimental group (50%) will be started on 100mg AZD0530 daily
AZD0530 125mg daily
Patients with plasma drug level \<100ng/ml after 2 weeks of 100mg AZD0530 daily will receive 125mg daily of AZD0530.
Placebo
50% of patients will receive placebo treatment for the duration of the study.
Mount Sinai School of Medicine, New York
University of Rochester Medical Center, Rochester
University of Pittsburgh, Alzheimer's Disease Research Center, Pittsburgh
Georgetown University, Washington D.C.
Wake Forest University Health Sciences, Winston-Salem
Roper St. Francis Hospital, Charleston
Wien Center for Clinical Research/Mount Sinai Medical Center, Miami Beach
University of South Florida - Health Byrd Alzheimer Institute, Tampa
University of Kentucky, Lexington
Indiana University, Indianapolis
University of Iowa, Iowa City
Northwestern University, Chicago
Rush University Medical Center, Chicago
Barrow Neurological Institute, Phoenix
Banner Sun Health Research Institute, Sun City
University of California, Los Angeles, Los Angeles
Oregon Health & Science University, Portland
University of Washington, Seattle
Yale Alzheimer's Disease Research Unit, New Haven
Brigham and Women's Hospital, Boston
University of Michigan, Ann Arbor, Ann Arbor
University of British Columbia, Clinic for AD & Related Disorders, Vancouver
Collaborators (1)
Alzheimer's Therapeutic Research Institute
OTHER
Yale University
OTHER